Nek­tar takes a hit as the FDA swerves away from opi­oid re­views — leav­ing NK­TR-181 in lim­bo

Nek­tar Ther­a­peu­tics took an­oth­er hit on Thurs­day af­ter the biotech re­port­ed that its opi­oid pain drug NK­TR-181 was be­ing put on hold at the FDA.

In an SEC fil­ing the com­pa­ny re­port­ed that the agency “con­tin­ues to con­sid­er a num­ber of sci­en­tif­ic and pol­i­cy is­sues re­lat­ing to this class of drugs” and would be post­pon­ing their planned Ad­Comm next month. Their Au­gust 29 PDU­FA date? Well, the FDA might not meet that.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER